Fredrik Nilsson
About
In The Last Decade
Fredrik Nilsson
36 papers receiving 2.4k citations
Peers
Comparison fields: 5 of 104
- Molecular Biology 1.5k
- Radiology, Nuclear Medicine and Imaging 1.4k
- Oncology 637
- Ecology 197
- Renewable Energy, Sustainability and the Environment 195
Countries citing papers authored by Fredrik Nilsson
This map shows the geographic impact of Fredrik Nilsson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fredrik Nilsson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fredrik Nilsson more than expected).
Fields of papers citing papers by Fredrik Nilsson
This network shows the impact of papers produced by Fredrik Nilsson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fredrik Nilsson. The network helps show where Fredrik Nilsson may publish in the future.
Co-authorship network of co-authors of Fredrik Nilsson
This figure shows the co-authorship network connecting the top 25 collaborators of Fredrik Nilsson. A scholar is included among the top collaborators of Fredrik Nilsson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fredrik Nilsson. Fredrik Nilsson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | [The Swedish Dental and Pharmaceutical Benefits Agency's willingness to pay for new drugs has been analyzed]. | 6 |
| 2 | 1 | |
| 3 | 4 | |
| 4 | 135 | |
| 5 | 70 | |
| 6 | Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. | 73 |
| 7 | 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. | 85 |
| 8 | 446 | |
| 9 | 78 | |
| 10 | 56 | |
| 11 | 100 | |
| 12 | 146 | |
| 13 | 80 | |
| 14 | 158 | |
| 15 | 34 | |
| 16 | 56 | |
| 17 | 5 | |
| 18 | 39 | |
| 19 | 42 | |
| 20 | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.